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S U M M A R Y
Objectives: The aim of this study was to review the epidemiology of cases of Middle East respiratory
syndrome coronavirus (MERS-CoV) reported in the Kingdom of Saudi Arabia from 2012 when the ﬁrst
MERS-CoV was conﬁrmed up to July 2015.
Methods: MERS-CoV data were obtained from the Saudi Ministry of Health for the period 2012 to July
2015. Descriptive statistics were used to summarize the results regarding the risk factors and mortality
of MERS-CoV infection.
Results: In this series, the risk factors and outcomes of 939 cases of MERS-CoV occurring in the last
3 years are described. The majority of the affected patients were aged 40 years (n = 657; 70%). Of the
657 patients aged 40 years, 377 (57.3%) died.
Conclusions: The case-fatality ratio was found to increase signiﬁcantly with age. It ranged from 12.5% in
those aged 19 years to 86.2% in those aged 80 years. The results conﬁrmed the association between
severe MERS-CoV illness and patients with a pre-existing health morbidity. The duration from symptom
onset to admission was not statistically associated with the disease outcome.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Middle East respiratory syndrome coronavirus (MERS-CoV)
emerged in the Kingdom of Saudi Arabia in 2012.1,2 Although
MERS-CoV is thought to be a zoonosis, probably involving
dromedary camels,3 clusters due to human-to-human transmis-
sion are well recognized.4–6 Locally acquired cases have been
reported primarily in countries of the Middle East including Iran,
Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab
Emirates, and Yemen; imported cases (or import-related cases)
have also occurred in Algeria, Austria, China, Egypt, France,
Germany, Greece, Italy, Malaysia, Netherlands, Philippines, South
Korea, Thailand, Tunisia, Turkey, UK, and the USA.7
The aim of this study was to review the epidemiology of cases of
MERS-CoV in the Kingdom of Saudi Arabia prior to July 2015.
2. Methods
Data were obtained from the Saudi Ministry of Health for the
period 2012 to July 2015. Cases were deﬁned as patients with a* Corresponding author. Tel.: +61 406548300.
E-mail address: Abdullah.sahaﬁ@monash.edu (A.J. Alsahaﬁ).
http://dx.doi.org/10.1016/j.ijid.2016.02.004
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).positive nucleic acid test for MERS-CoV, whether diagnosed due to
clinical presentation because of illness, or active surveillance in
known contacts. Primary cases were deﬁned as patients who were
diagnosed with MERS-CoV following presentation for medical care,
and secondary cases were patients who were tested as a contact of
a known case, whether in a household, as an inpatient in hospital,
or as a healthcare worker caring for a case.
Descriptive statistics were used to summarize the results.
Proportions were compared between groups using the Chi-square
test, and continuous variables were compared using the Mann–
Whitney test or Kruskal–Wallis test, as appropriate. Univariate and
a multivariate logistic regression models were used to determine
risk factors for mortality, excluding asymptomatic patients and
those for whom medical morbidities or the outcome were not
ascertained. Statistical tests were performed using Stata 14 for
Windows (StataCorp, College Station, TX, USA).
This study was approved by the Ministry of Health of the
Kingdom of Saudi Arabia.
3. Results
During the period 2012 to July 2015, 939 cases of MERS-CoV
were reported to the Saudi Ministry of Health. Of these,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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3.2% were children (<20 years) (Table 1). Compared to the other
groups, a higher proportion were female in the group of healthcare
workers. The largest proportion of cases were from the Riyadh
region (n = 369; 39.3%), followed by Jeddah (n = 195; 20.8%) and
the Eastern region (n = 125; 13.3%). The majority of cases in Riyadh
(n = 197; 53.4%) and Jeddah (n = 197; 91.8%) occurred in 2014,
while most cases in the Eastern region (n = 67; 53.6%) were
reported in 2015.
Primary cases and secondary case hospital inpatients were
older than household contacts and secondary case healthcare
workers (Figure 1).
The distribution of MERS-CoV cases in the Kingdom of Saudi
Arabia from September 2012 to July 2015 by month of symptom
onset showed no speciﬁc constant seasonal pattern. Most of the
cases occurred during the ﬁrst 6 months of the year (Figure 2).
3.1. Clinical presentation
The location of diagnosis was reported for 788 patients. Of
these, 329 patients were diagnosed following presentation with
illness. Of the remaining 459 patients who were diagnosed as
contacts, 114 were contacts of known cases in the community,
174 were inpatient contacts of known cases, and 171 were
healthcare worker contacts (Table 1). Of the secondary cases,
93 were asymptomatic; this proportion was highest in healthcare
workers (32%), followed by household cases (23%).
3.2. Risk factors
Medical comorbidities were reported in 421 patients (Table 1).
Overall, 351 patients (44%) had one or more comorbidity; the
proportion with comorbidities was higher in patients who were
>60 years of age and those who were secondary cases in hospital
inpatients. Diabetes was common in all groups (53% overall).Table 1
Characteristics of MERS-CoV cases in the Kingdom of Saudi Arabia prior to July 2015, 
Primary Secondary 
Household Inpatient 
Numberb 329 114 174 
Year 
2012 3 (0.9%) 2 (1.8%) 0 (0.0%) 
2013 38 (11.6%) 26 (22.8%) 40 (23.0%)
2014 168 (51.1%) 55 (48.2%) 73 (42.0%)
2015 120 (36.5%) 31 (27.2%) 61 (35.1%)
Age group, years 
19 7 (2.1%) 16 (14.0%) 4 (2.3%) 
20–39 52 (15.8%) 40 (35.1%) 25 (14.4%)
40–59 135 (41.0%) 41 (36.0%) 53 (30.5%)
60–79 112 (34.0%) 15 (13.2%) 71 (40.8%)
80 23 (7.0%) 2 (1.8%) 21 (12.1%)
Male 250 (76.0%) 80 (70.2%) 124 (71.3%
Resident of KSA 236 (71.7%) 92 (80.7%) 144 (82.8%
Comorbidities
Diabetes 116/198 (58.6%) 19/38 (50.0%) 49/99 (49.
Hypertension 96/198 (48.5%) 13/38 (34.2%) 58/99 (58.
Renal disease 22/198 (11.1%) 2/38 (5.3%) 31/99 (31.
Pulmonary disease 19/198 (9.6%) 0/38 (0.0%) 11/99 (11.
Cardiac disease 37/198 (18.7%) 8/38 (21.1%) 34/99 (34.
Cancer 9/198 (4.5%) 1/38 (2.6%) 9/99 (9.1%
Other chronic disease 46/198 (23.2%) 2/38 (5.3%) 32/99 (32.
Presentation: asymptomatic 0/325 (0.0%) 25/110 (22.7%) 4/172 (2.3
Notiﬁcation from symptom
onset >7 days
146/317 (46.1%) 28/99 (28.3%) 38/167 (22
Died 184/325 (56.6%) 18/110 (16.4%) 132/172 (7
MERS-CoV, Middle East respiratory syndrome coronavirus; HCW, healthcare worker; K
a p-Values represent results of the Chi-square test for the null hypothesis of no diffe
acquisition.
b Denominator unless reported otherwise.3.3. Mortality
The case-fatality ratio increased with age, with a mortality of
12.5% in children aged <20 years rising to 86% in elderly patients
aged >80 years. In the univariate analysis of patients for whom
complete data were available and excluding asymptomatic cases,
acquisition as a hospital inpatient, hypertension, renal disease,
cardiac disease, and cancer were positively associated with
mortality (Table 2). On multivariate analysis, age >80 years,
cardiac disease, and cancer were independently associated with
mortality. Compared to primary cases, mortality was lower in
household cases and healthcare workers. The duration from
symptom onset to admission was not statistically associated with
the disease outcome.
MERS cases were notiﬁed to the Saudi Ministry of Health (MOH)
from different regions of the Kingdom. The present data showed
that 564 (65.1%) patient cases were notiﬁed within 7 days after the
onset of symptoms, while 301 (34.8%) patient cases were notiﬁed
at >7 days after symptom onset (Table 1).
4. Discussion
In this series, the risk factors and outcomes of more than
900 cases of MERS-CoV occurring over 3 years are described. These
represent 60% of the 1570 cases reported worldwide.
A distinct clinical proﬁle was found in the different populations
based on their likely location of acquisition, which reinforces the
association of chronic comorbidity and severe infection. While
previous studies have noted a lower mortality in secondary cases
consistent with a detection bias in primary cases,8 it was found
that the case fatality varied in the different groups with secondary
infection. Patients who presented with primary infection were
more severely unwell but had a similar mortality as hospital
inpatients who acquired the infection in hospital. Healthcare
workers and household contacts had a lower mortality, reﬂecting aby location of acquisition
Unknown Total p-Valuea
HCW
171 151 939
<0.001
0 (0.0%) 0 (0.0%) 5 (0.5%)
 26 (15.2%) 6 (4.0%) 136 (14.5%)
 127 (74.3%) 134 (88.7%) 557 (59.3%)
 18 (10.5%) 11 (7.3%) 241 (25.7%)
<0.001
0 (0.0%) 5 (3.3%) 32 (3.4%)
 104 (60.8%) 29 (19.2%) 250 (26.6%)
 62 (36.3%) 54 (35.8%) 345 (36.7%)
 5 (2.9%) 50 (33.1%) 253 (26.9%)
 0 (0.0%) 13 (8.6%) 59 (6.3%)
) 71 (41.5%) 99 (65.6%) 624 (66.5%) <0.001
) 29 (17.0%) 112 (74.2%) 613 (65.3%) <0.001
5%) 10/34 (29.4%) 30/52 (57.7%) 224/421 (53.2%) 0.014
6%) 6/34 (17.6%) 27/52 (51.9%) 200/421 (47.5%) 0.001
3%) 1/34 (2.9%) 12/52 (23.1%) 68/421 (16.2%) 0.001
1%) 2/34 (5.9%) 5/52 (9.6%) 37/421 (8.8%) 0.18
3%) 3/34 (8.8%) 15/52 (28.8%) 97/421 (23.0%) 0.004
) 0/34 (0.0%) 4/52 (7.7%) 23/421 (5.5%) 0.13
3%) 4/34 (11.8%) 14/52 (26.9%) 98/421 (23.3%) 0.003
%) 56/170 (32.9%) 8/147 (5.4%) 93/924 (10.1%) 0.001
.8%) 27/146 (18.5%) 62/137 (45.3%) 301/866 (34.8%) 0.001
6.7%) 15/170 (8.8%) 76/147 (51.7%) 425/924 (46.0%) 0.001
SA, Kingdom of Saudi Arabia.
rence in proportions across groups, excluding patients with an unknown source of
Figure 1. Age distribution of MERS-CoV cases reported in the Kingdom of Saudi Arabia during the period 2012 to July 2015, by location of acquisition.
Table 2
Factors associated with mortality in 403 symptomatic MERS-CoV cases in the
Kingdom of Saudi Arabia for the period 2012 to July 2015, for whom comorbidities
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well.
The present ﬁndings conﬁrm the association between comor-
bidities in patients and severe illness.9–11 Previous studies have
deﬁned obesity, diabetes, and renal disease as risk factors when
comparing cases to test-negative hospital-based controls with
respiratory illnesses.8–10 Diabetes was very common across all
groups, including healthcare workers. The high prevalence of renal
disease in hospital inpatients reﬂects the wards in which
nosocomial outbreaks occurred.
Patients with secondary infections were detected by active
surveillance and therefore are more likely to reﬂect the full
spectrum of illness. Of note, a signiﬁcant proportion of household
infections and healthcare worker infections were reported to be
asymptomatic, and previous cases have been noted to have
prolonged viral shedding.5,12–14 Similar to a previous study, it was
found that acute disease (with a short duration of symptoms at the
time of hospital admission) was not associated with increased
mortality.11 It was reassuring to ﬁnd that the majority of cases
were admitted within a week, as early diagnosis is required toFigure 2. Distribution of MERS-CoV cases in the Kingdom of Saudi Arabia during the
period 2012 to July 2015, by month of onset of symptoms.ensure that control measures are effective.15 A small proportion
who were asymptomatic was noted; the clinical signiﬁcance of
asymptomatic infection, and particularly the potential for trans-
mission, is not yet known.
There were several limitations in reviewing this public health
database. The data reported here represent almost 90% of the
1045 laboratory-conﬁrmed cases of MERS-CoV reported in the
Kingdom of Saudi Arabia, but the reasons for the missing data are
not apparent. Available clinical data on diagnosis and treatment
were scarce, and a signiﬁcant proportion had missing data on
comorbidities. As primary cases were detected following presen-
tation with illness, unknown selection biases may be present. It is
not possible to comment on risk factors for the acquisition of
MERS-CoV without a control group without infection.and the outcome were ascertained
Unadjusted OR (95% CI) Adjusted OR (95% CI)
Age group, years
19 0.40 (0.04, 3.95) 0.37 (0.03, 3.95)
20–39 0.54 (0.30, 0.96) 0.64 (0.32, 1.27)
40–59 1 1
60–79 2.44 (1.51, 3.93) 1.49 (0.87, 2.56)
80 6.51 (2.38, 17.82) 4.07 (1.41, 11.78)
Male 0.93 (0.60, 1.45) 0.78 (0.45, 1.34)
Comorbidities
Diabetes 1.43 (0.96, 2.11) 0.86 (0.49, 1.52)
Hypertension 2.34 (1.56, 3.49) 1.41 (0.80, 2.48)
Renal disease 1.84 (1.06, 3.18) 1.06 (0.56, 2.03)
Pulmonary disease 1.38 (0.68, 2.79) 1.10 (0.48, 2.54)
Cardiac disease 3.86 (2.25, 6.60) 2.80 (1.52, 5.16)
Cancer 6.46 (1.89, 22.10) 5.98 (1.64, 21.79)
Location of acquisition
Primary 1 1
Secondary/household 0.24 (0.10, 0.58) 0.25 (0.09, 0.68)
Secondary/inpatient 3.32 (1.90, 5.82) 2.61 (1.41, 4.82)
Secondary/HCW 0.10 (0.03, 0.35) 0.17 (0.05, 0.59)
Unknown 1.20 (0.63, 2.26) 1.02 (0.50, 2.06)
MERS-CoV, Middle East respiratory syndrome coronavirus; OR, odds ratio; CI,
conﬁdence interval; HCW, healthcare worker.
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